Stay updated with breaking news from Dermavant Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Patients from PSOARING 3 who completed the survey preferred tapinarof to prior topical treatments with 81.7% considering it more effective Dermavant Sciences, a clinical-stage biopharmaceutical company
- Patient satisfaction results from tapinarof long-term extension study for the treatment of plaque psoriasis in adults to be presented - Dermavant Sciences, a clinical-stage biopharmaceutical company
Healio Psoriatic Disease | Topical steroids have remained a mainstay first-line treatment for psoriasis, but two new drugs in development aim to revolutionize how topical drugs are used in treatment of the disease.“We’ve had a decent amount of minor innovation in psoriasis,” Mark G. Lebwohl, MD, dean for clinical therapeutics and chair emeritus of the Kimberly and Eric J. Waldman Department of Dermatology
Benefits of treatment with tapinarof 1% were seen even with intermittent use in the extension trial.
Psoriasis Market to Exhibit Promising Growth at a CAGR of 5.6% in the United States during the Study Period [2018-2030], States DelveInsight LAS VEGAS, May 11, 2021 /PRNewswire/ -- DelveInsight's " Psoriasis Market" report provides a thorough comprehension of the Psoriasis, historical and forecasted epidemiology, and the Psoriasis market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Psoriasis market report also proffers an analysis of the current Psoriasis treatment algorithm/practice, market drivers, market barriers, and unmet m...